Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YQ1 with Cisplatin-based Chemotherapy in Advanced EGFR/ALK Wild Type NSCLC
NCT02967497Phase 2Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 2, randomised, open-label trial of UanQiHuoLi Tang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Taipei Veterans General Hospital. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
UanQiHuoLi Tang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02967497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967497.